Mood stabilizers and psilocybin.
5 records in this group. 3 have published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.
Overview
Reviewed 2026-10-25Lithium taken with a classic psychedelic has been linked to seizures. In 62 self-selected online reports (from Erowid, Shroomery and Reddit) of lithium with a classic psychedelic, 47% described seizures and 39% described needing medical attention; reports like these cannot give a rate (Nayak 2021). A case report describes three seizures after LSD in an adolescent recently started on low-dose lithium, who was also taking fluoxetine and bupropion (Edwards 2024). With LSD, long-term lithium intensified the response in the 3 people interviewed (Bonson & Murphy 1996).
In the same online dataset, none of 34 reports of lamotrigine with a classic psychedelic described a seizure, and most described no change in the experience; 34 self-selected reports cannot show that a risk is absent (Nayak 2021).
Psilocin, psilocybin's active form, is cleared mainly by glucuronidation and by MAO-A (Sarparast 2022). Carbamazepine induces liver enzymes and valproate inhibits UGT2B7, one of the glucuronidation enzymes (carbamazepine prescribing information; Rowland 2006), so in theory they could lower or raise psilocin levels; neither has been measured with psilocybin. Lithium and valproate were among six medications in one case report in which psilocybin mushrooms produced no noticeable subjective effects (Barnett 2024).
Lithium is named in state rules. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Rule 2.2(A)(7) lists conditions under which they may: a referral, medical clearance, or a consultation and risk review with a licensed provider, with documentation, and a safety plan and written informed consent where heightened risk is found. Rule 2.5(A)(2) covers Clinical Facilitators (4 CCR 755-1). Under Oregon's rules, a client who answers yes to the Client Information Form's question on taking the prescription drug lithium in the last 30 days may not participate in an administration session (OAR 333-333-5050).
Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.
- Nayak SM, Gukasyan N, Barrett FS, et al. Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures. Pharmacopsychiatry 2021.
- Edwards C, Van Gerpen S, Anand V. New-onset seizures in an adolescent following use of LSD while on low-dose lithium therapy: a case study. S D Med 2024;77(1):31–35.
- Bonson KR, Murphy DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 1996;73:229–233.
- Sarparast A, Thomas K, Malcolm B, Stauffer CS. Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review. Psychopharmacology 2022;239(6):1945–1976.
- Rowland A, Elliot DJ, Williams JA, et al. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos. 2006;34(6):1055-62. doi:10.1124/dmd.106.009340
- Barnett BS, Koons CJ, Van den Eynde V, et al. Hypertensive emergency secondary to combining psilocybin mushrooms, extended release dextroamphetamine-amphetamine, and tranylcypromine. J Psychoactive Drugs 2024;57(3):297–303.
- Tegretol (carbamazepine) prescribing information (DailyMed)
- 4 CCR 755-1, official Secretary of State text, effective 03/30/2025; Rule 5.4 emergency rule effective 12/05/2025 (official Colorado rule text)
- OAR 333-333 (Psilocybin), official Secretary of State text; OAR 333-333-5050 last amended 01/01/2025; OHA Client Information Form updated 01/01/2026 (official Oregon rule text)
Also searched as mood stabilizer
01 What the evidence covers
Best evidence available per medication| 3 | Case reports Case reports or online surveys |
| 2 | No psilocybin data No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts |
02 Each medication
A to ZPartial seizures with complex symptoms; Generalized tonic-clonic seizures
It may weaken psilocybin by speeding how the body clears psilocybin (untested). Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Partial-onset (focal) seizures; Primary generalized tonic-clonic seizures
In 34 reports with classic psychedelics like psilocybin, none described a seizure; most noted no change. Stopping it suddenly after regular use can cause seizures.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Bipolar I disorder (manic or mixed episodes); Bipolar I disorder (maintenance)
In 62 online reports of lithium with psychedelics like psilocybin, 47% described seizures and 39% needed medical attention.
CO: named in rule · OR: named in rule · NM: rules not final
- Lithium orotateEvidence: No psilocybin data
Supplements and over the counter
Not studied with psilocybin; prescription lithium with classic psychedelics was linked to seizures, but whether this applies at supplement doses is unknown.
CO: unsettled · OR: unsettled · NM: rules not final
Complex partial (focal) seizures; Absence seizures (simple and complex), alone or with other seizure types
In one case, psilocybin mushrooms with valproate, phenelzine and other drugs had no noticeable effect. It may also slow how the body clears psilocybin.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
03 Properties the records flag
Records with each flag| 4 | Withdrawal or rebound if stopped abruptly |
| 3 | Psychiatric reactions |
| 2 | Dehydration or electrolyte risk |
| 2 | Liver injury |
| 2 | Sedating or CNS depressant |
| 1 | Anticholinergic |
| 1 | Lowers seizure threshold or carries seizure risk |
| 1 | Serotonergic |
| 1 | Speeds up drug metabolism |
| 1 | UGT inhibition (theoretical effect on psilocin levels) |
Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.
04 State rules
Official text governs1 of 5 named by a provision. 1 unsettled.
Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. Lithium is named in rule. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent. A Clinical Facilitator who does not prescribe lithium or antipsychotics within their secondary license needs clearance from, or a consultation and risk review with, such a provider (2.5(A)(2)).
Colorado rules 2.2(A)(6) and 2.2(A)(7) both address participants taking lithium or an antipsychotic, and the rule text does not state how the two fit together. The rule names “lithium” without stating its form, dose or prescription status, so whether it covers low-dose lithium orotate supplements is unsettled; the regulator has not addressed this. Colorado rule 2.2(A)(6) states that Facilitator licensees may not provide natural medicine services to participants taking lithium or antipsychotic medications. Under 2.2(A)(7), services may proceed only after a referral from a licensed provider (MD, DO, APN, PA or clinical facilitator), medical clearance from the participant's provider, or a consultation and risk review with a provider licensed to diagnose and treat the condition identified as a risk factor; the Facilitator documents the consultation, and where it identifies heightened risk, the rule requires a safety plan and written informed consent. A Clinical Facilitator who does not prescribe lithium or antipsychotics within their secondary license needs clearance from, or a consultation and risk review with, such a provider (2.5(A)(2)).
Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. 3 of the 5 medications in this group are psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.
1 of 5 named by a provision. 1 unsettled.
Lithium is named on Oregon's required Client Information Form. A client who has taken lithium in the last 30 days may not participate in an administration session.
Oregon's required Client Information Form asks whether the client has taken “the prescription drug Lithium” in the last 30 days; a client who answers yes may not participate in an administration session. Whether this covers non-prescription lithium orotate supplements is unsettled; the regulator has not addressed this.
Rules not final; the proposed rules reviewed name no medication in this group.
05 Studies cited in this group
Records citing eachRelated classes
- Seizure medications3 shared
Records reviewed 2026-10-14 to 2026-10-25. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z